Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Observer-blind, Randomized, Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019), Administered as a Booster Dose to Adults, Who Previously Received Primary Series of a COVID-19 Vaccine

NCT05188677 is registered in ClinicalTrials.gov with Clover Biopharmaceuticals AUS Pty as lead sponsor.

NCT NCT05188677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05188677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Observer-blind, Randomized, Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019), Administered as a Booster Dose to Adults, Who Previously Received Primary Series of a COVID-19 Vaccine
Lead sponsor
Clover Biopharmaceuticals AUS Pty
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2022
Completion date
June 6, 2023
Enrollment
1,831 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19